Updates in adjuvant systemic therapy for melanoma

Kwak, Minyoung; Farrow, Norma E.; Salama, April K.S.; Mosca, Paul J.; Hanks, Brent A.; Slingluff, Craig L.; Beasley, Georgia M.

doi:10.1002/jso.25298

Cited by 37 publications

(30 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dacarbazine (DTIC) has been recognized as the only chemotherapy drug approved by the Food and Drug Administration (FDA) for progressive MM since 1972 [18]. In recent years, with the development of genetic testing technology, exploration of immune-and targeted-therapy, immune therapy has been gradually used for these patients [20,21]. Clinical studies showed that the skin melanoma with more mutated BRAF gene mutation and AM accounted for only 17% of BRAF gene mutations, and KIT gene mutation was 15% ~ 40% (3,22).…”

Section: Discussionmentioning

confidence: 99%

“…Clinical studies showed that the skin melanoma with more mutated BRAF gene mutation and AM accounted for only 17% of BRAF gene mutations, and KIT gene mutation was 15% ~ 40% (3,22). Additionally, the efficacy of nivolumab in melanoma has been recognized [21]. However, there is still lack of objective data to evaluate AM patients in China, thus, the efficacy of targeted therapy and immunotherapy needs to be studied for a long period of time.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective study of acral melanoma that happened on foot

Yao

Cai

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

Methods: The aim was to investigate the epidemiological, clinical, and prognostic features of acral melanoma (AM) that occurred on foot, and to provide associated data for further study. A retrospective study was performed on patients with malignant melanoma (MM) who were treated in our hospital from January 2015 to January 2019. The tumor site was screened by foot. Basic data (e.g., gender, age, occupation, tumor location and etiology) of eligible patients, tumor-related data (such as tumor thickness, lymph node metastasis, and systemic metastasis), surgical related data (e.g., surgical site, operation time, bleeding volume, postoperative drainage time and volume), and prognostic data (including local recurrence or metastasis) were extracted. Survival analysis was used to study event-free survival (EFS) and overall survival (OS) and factors influencing survival of patients. Results: A total of 109 patients with AM happened on foot, including 52 males and 57 females, male/female = 0.91, were involved. The patients’ age was 58.31±12.13 years old. The occupations included 69 (63.3%) of farmers, 20 (18.3%) of freelance work, 4, 10 and 6 (18.4% in total) of others, including workers, students, and retirees. Tumor locations were 19 (17.4%) of the thumbs, 9 (8.3%) of other toes, 54 (49.5%) of the inner and outer soles, 20 (18.3%) of the heels, and 7 (6.4%) of the back foot. The causes were 57 cases (52.3%) of malignant nevus, 7 cases (6.4%) of trauma stimulation, and 45 cases (41.3%) without inducement. Additionally, 29 cases (26.6%) were newly diagnosed and treated in our hospital, and 80 cases (73.4%) were previously treated in external hospitals. Symptoms of nudes or ulceration lasted for 1 to 15 months, with an average of 5.92 months. The main surgical methods are tumor (enlarged) resection, lymph nodes resection, and combined resection of tumor and lymph nodes. During the treatment, 45 patients needed additional surgery. At the last follow-up, 8 cases had tumor recurrence, 43 cases had lymph node metastasis, 29 patients (stage IV) had metastasis in vital viscera, and 12 patients died. The EFS was 16 months, and OS was 31 months on average. Univariate analysis suggested that there was a correlation between occupations and EFS, locations and OS. Conclusions: Middle-aged and elderly manual workers were found as the main population of AM that happened on foot. The tumor appeared at the weight-bearing area of the soles and heels. The proportion of metastasis was high, while the prognosis was poor. Preventive resection of precancerous lesions and early diagnosis and treatment of tumors are the primary tasks to improve the efficacy and survival of patients

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A retrospective study of acral melanoma that happened on foot

Yao

Cai

Wang

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Furthermore, ICB and BRAF/MEKi have demonstrated significant survival benefits in stage III melanoma. [22][23][24][25] .Neoadjuvant sequencing of these novel therapies is feasible for clinically evident disease, and, in a subset of patients, can result in a complete pathologic response. [26][27][28] As the trend continues toward less extensive locoregional surgery for melanoma, it must be balanced with a better understanding of risk patterns for recurrence in the context of novel systemic therapies.…”

Section: Discussionmentioning

confidence: 99%

Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background-Nodal observation is safe for patients with microscopic melanoma metastasis in a sentinel lymph node (LN). Complete LN dissection (CLND) remains the standard of care for patients with clinically evident LN (cLN) metastases, even though about 40% have only one pathologic LN (pLN). We sought to identify clinical features associated with having one pLN among patients with cLNs. Methods-Patients at three melanoma centers who underwent CLND for cLNs were identified. Clinicopathologic and imaging characteristics associated with one pLN were determined by multivariable logistic regression and classification tree analysis. Results-Of 190 patients, 90 (47.4%) had one pLN and 100 (52.6%) had more than one pLN. By multivariable logistic regression, extremity versus truncal primary (odds ratio [OR] 2.15, p = 0.012), axillary versus superficial inguinal location (OR 3.89, p = 0.009), and preoperative crosssectional imaging demonstrating more than one versus one cLN (OR 17.1, p < 0.001) were associated with more than one pLN. The negative predictive value for additional pathologic nodal disease of preoperative imaging was 70.9%, increasing to 74.4% for positron emission tomography/computed tomography. In the subgroup of patients with one cLN, the classification tree identified two groups with < 10% risk of additional pLNs: (1) Breslow thickness > 6.55 mm

show abstract

“…Despite much research, the mechanisms of the occurrence and development of melanoma remains unclear. Surgery, radiotherapy and chemotherapy have long been the main methods for melanoma treatment, but these methods also have some problems, such as severe trauma, obvious side effects and low patient tolerance [31]. With the recent process in treatment, immune therapies and targeted therapies are two main treatment approaches for patients with advanced melanoma, but both still have limitations, and not all patients experience sustained responses [32].…”

Section: Discussionmentioning

confidence: 99%

Overexpression of RACK1 Predicts Poor Prognosis in Melanoma

Shen

Hua

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Melanoma is a highly malignant skin cancer with limited treatment options, the mechanism of the occurrence and development of melanoma is still unclear till now. Receptor for activated C kinase 1 (RACK1) is a scaffolding protein that mediates multiple signaling pathways; it interconnects distinct signaling pathways to control essential cellular processes. RACK1 was reported as an oncogene in human tumorigenesis, but little is known about its role in melanoma. This study aimed to investigate the expression of RACK1 in patients with melanoma and to reveal its possible functions in melanoma cells. The expression profiles of RACK1 detected in tumor tissues from melanoma patients showed that RACK1 was higher in tumor tissues, and its expression level was well associated with the clinical progression of melanoma (TNM stage, P=0.009). Furthermore, RNA interfering (RNAi) knockdown of RACK1 could efficiently suppress the proliferation, migration and invasion of A375 and A875 cells and promote their apoptosis. Taken together, these results suggest that RACK1 may be a poor prognostic factor in human melanoma, and it may be a new therapeutic target for melanoma treatment.

show abstract

Updates in adjuvant systemic therapy for melanoma

Cited by 37 publications

References 68 publications

A retrospective study of acral melanoma that happened on foot

A retrospective study of acral melanoma that happened on foot

Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis

Overexpression of RACK1 Predicts Poor Prognosis in Melanoma

Contact Info

Product

Resources

About